vorinostat has been researched along with wp1066 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, N; Ding, M; Fang, XS; Feng, LL; Jiang, YJ; Li, PP; Liu, X; Lu, K; Wang, N; Wang, X; Zhang, J; Zhou, XX | 1 |
| Chen, N; Feng, LL; Ge, XL; Geng, LY; Li, PP; Li, XY; Lu, K; Wang, X; Zhou, XX | 1 |
2 other study(ies) available for vorinostat and wp1066
| Article | Year |
|---|---|
The STAT3 inhibitor WP1066 reverses the resistance of chronic lymphocytic leukemia cells to histone deacetylase inhibitors induced by interleukin-6.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; bcl-X Protein; Cell Survival; Coculture Techniques; Drug Resistance, Neoplasm; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Interleukin-6; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Panobinostat; Phosphorylation; Protein Processing, Post-Translational; Pyridines; STAT3 Transcription Factor; Stromal Cells; Tumor Cells, Cultured; Tyrphostins; Vorinostat | 2015 |
The STAT3 inhibitor WP1066 synergizes with vorinostat to induce apoptosis of mantle cell lymphoma cells.
Topics: Antineoplastic Agents; Apoptosis; B-Lymphocytes; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Histone Deacetylases; Humans; Hydroxamic Acids; Lymphoma, Mantle-Cell; Pyridines; RNA, Messenger; Signal Transduction; STAT3 Transcription Factor; Tyrphostins; Vorinostat | 2015 |